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Abstract
Introduction: Toll-like receptors (TLRs) are likely to play crucial roles in the pathogenesis of rheumatoid arthritis
(RA). The aim of this study was to determine the key TLRs in synovium and explore their roles in the activation of
fibroblast-like synoviocytes (FLSs) mediated by T cells in arthritis.
Methods: Pristane-induced arthritis (PIA) was established by subcutaneous injection with pristane at the base of
the rat’s tail. TLR expression in synovium from PIA rats was detected at different time points by performing real-
time PCR. Polyinosinic:polycytidylic acid (poly(I:C)) was intra-articularly administrated to PIA rats, and arthritis was
monitored macroscopically and microscopically. Synovial TLR3 was detected by immunohistochemical staining. Rat
FLSs were stimulated with pristane-primed T cells or pristane-primed, T-cell conditioned medium. The intervention
of TLR3 in FLSs was achieved by specific short-hairpin RNA (shRNA) or an antibody. The migration ability of FLSs
was measured by using the scratch test, and gene expression was detected by using real-time PCR. FLSs from RA
patients were stimulated with various cytokines and TLR ligands, and TLR3 expression was detected by performing
real-time PCR. In addition, with different concentrations of poly(I:C) stimulation, TLR3 expression of FLSs from RA
patients and patients with osteoarthritis (OA) was compared.
Results: Synovium TLR3 displayed early and persistent overexpression in PIA rats. TLR3 was expressed in FLSs, and
local treatment with poly(I:C) synergistically aggravated the arthritis. Rat FLSs co-cultured with pristane-primed T
cells showed strengthened migration ability and significant upregulation of TLR3, IFN-b, IL-6 and matrix
metalloproteinase 3 (MMP3) expression, which could also be induced by pristane-primed, T-cell conditioned
medium. The upregulation of cytokines and MMPs was blocked by shRNA or TLR3 antibodies. In RA FLSs with
cytokine or TLR ligand stimulation, TLR3 expression exhibited remarkable upregulation. Furthermore, RA FLSs
showed higher reactivity than OA FLSs to poly(I:C).
Conclusions: TLR3 in the synovium of PIA rats was overexpressed, and activation of the TLR3 signaling pathway
could aggravate this arthritis. The induction of TLR3 in FLSs resulted from T cell-derived inflammatory stimulation
and could further mediate FLS activation in arthritis. We conclude that TLR3 upregulation of FLSs activated by T
cells results in articular inflammation.
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Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by synovial inflammation, cartilage
and bone erosion and pannus formation [1,2]. Synovitis
manifesting synoviocyte proliferation and activation has
been considered the main cause of the secretion of
proinflammatory cytokines and chemokines, the recruit-
ment of inflammatory cells and the production of matrix
metalloproteinases (MMPs) [3,4]. Accumulating evi-
dence highlights a role of Toll-like receptors (TLRs) in
mediating the synovial inflammatory response [5,6].
TLRs belong to the pattern recognition receptor family
and connect innate and adaptive immunoresponses. Sti-
mulation of TLRs with their ligands activates NF-B,
mitogen-activated protein kinase and IFN regulatory factor
pathways [7]. A direct consequence of antigen-presenting
cell activation by TLRs is to enhance the secretion of cyto-
kines, as well as the upregulation of major histocompat-
ibility complex (MHC) and costimulatory molecule
expression, which facilitate the activation of adaptive
immune responses [8].
It has been demonstrated that many TLRs are constitu-
tively expressed in immune cells and synoviocytes. Pre-
vious studies have shown that TLR2, TLR3, TLR4 and
TLR7 are overexpressed in the synovial tissue of RA
patients [9-11] and that TLR2 and TLR4 expression in
peripheral blood cells and macrophages from RA patients
is also upregulated [12]. Interestingly, TLR ligands, such
as peptidoglycan (PGN), CpG DNA, heat shock proteins
and RNA from both infectious organisms and endogen-
ous necrotic cells, have been identified in the joints of
RA patients [13-15]. Such exogenous and endogenous
TLR ligands have been shown to induce arthritis in mice
upon intra-articular injection [16,17]. The synoviocytes
activated by TLR ligands could produce proinflammatory
cytokines and chemokines, such as TNF-a,I L - 1 5 ,I F N - b,
granulocyte chemotactic protein 2, RANTES (regulated
on activation normal T-cell expressed and secreted) and
monocyte chemotactic protein 2, which might contribute
to synovitis maintenance and inflammatory cell infiltra-
tion [15,18-20]. Activated synoviocytes could also secrete
MMPs, RANKL (receptor activator of NF-B ligand) and
vascular endothelial growth factor, which are involved in
the cartilage degradation, joint destruction and angiogen-
esis in joints [10,21,22]. Thus, TLRs may play a vital role
in mediating the synovial inflammation in both RA and
experimental arthritis [23]. However, the relative role of
the different TLRs in mediating and regulating arthritis is
still unclear.
In a previous study, we found that TLR3 is the earliest
and most prominently upregulated TLR in splenic macro-
phages by screening the TLR expression profile in pris-
tane-induced arthritis (PIA), a MHC class II-restricted and
T-cell-dependent arthritis rat model, and that downregula-
tion of TLR3 expression modulates the severity of arthritis
[24]. These findings regarding TLR3 provide an explana-
tion for the initiation of the inflammatory response in
immune organs, but the roles of TLRs in local inflamma-
tion of joints are still unclear. We hypothesize that a TLR
may be induced by arthritogenic T cells and then mediates
the activation of synoviocytes in local inflammatory
responses. The aim of the present study was to answer the
question which TLR is probably the key TLR in synovium
in arthritis, whether triggering of the key TLR directly
affects arthritis severity and how the key TLR in synovio-
cytes is induced to mediate the local inflammatory
response.
Materials and methods
Rats
Dark Agouti (DA rats were bred in a specific pathogen-
free animal house at the Department of Genetics and
Molecular Biology, Xi’an Jiaotong University School of
Medicine, Shaanxi, People’s Republic of China. Age- and
sex-matched rats were used in all experiments, and each
group contained 8 to 10 rats 8 to 12 weeks old. The
experiments were approved by the Institutional Animal
Ethics Committee of the university.
Arthritis induction and evaluation
Arthritis was induced by a single subcutaneous injection
of 300 μL of pristane (ACROS Organics, Morris Plains,
NJ, USA) at the base of the rat’s tail. Arthritis develop-
ment and severity were monitored by the change in the
perimeter of the ankle and midpaw and assessed using a
macroscopic scoring system as described previously [25].
For pathological examination, ankle joints of rats were
sectioned and stained with H & E. The pathological sever-
ity of synovitis was estimated on the basis of four items:
(1) the thickness of the synovium lining layer, (2) pannus,
(3) synovium inflammatory cells and (4) angiogenesis.
Each pathological item was scored on a scale ranging from
0 (normal) to 3 (most severe). Finally, synovitis was esti-
mated by adding the scores on items one through four,
and the maximum histopathological score was 12 for each
ankle.
RNA quantitation
Rats were killed at day 0 (naive rats, D0), day 6 (D6), day
12 (D12) or day 26 (D26) after pristane injection, and the
synovium was collected for TLR expression quantitation.
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA), and cDNA was synthesized by using
the First Strand cDNA Synthesis Kit (Fermentas, Burling-
ton, ON, Canada). Real-time PCR was performed by
using iQ5 optical system software (Bio-Rad Laboratories,
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(TaKaRa, Ohtsu, Shiga, Japan) for TLR and cytokine
mRNA quantitation. Relative gene expression normalized
by b-actin was calculated by using the 2
-ΔΔCt method.
Information regarding primers, products and annealing
temperatures is given in Table 1.
Immunohistochemical staining
The paraffin-embedded ankle joints from each rat were
sectioned, and endogenous peroxidase was blocked with
0.3% H2O2 for 10 minutes. Each section was treated
with 10 M urea and Antigen Repair solution I (Wuhan
Boster Biological Technology, Ltd., Wuhan, China) for
Table 1 Primer information for real-time PCR
Gene accession number Sequence (5’-3’) Size, bp Annealing temperature, °C
tlr1 (rat)
[NM_001172120]
Forward CAGCAGCCTCAAGCATGTCTA 82 60
Reverse CAGCCCTAAGACAACAATACAATAGAAGA
tlr2 (rat)
[NM_198769]
Forward CTCCTGTGAACTCCTGTCCTT 74 60
Reverse AGCTGTCTGGCCAGTCAAC
tlr3 (rat)
[NM_198791]
Forward GATTGGCAAGTTATTCGTC 205 54
Reverse GCGGAGGCTGTTGTAGG
tlr4 (rat)
[NM_019178]
Forward GATTGCTCAGACATGGCAGTTTC 135 54
Reverse CACTCGAGGTAGGTGTTTCTGCTAA
tlr5 (rat)
[NM_001145828]
Forward GGGCAGCAGAAAGACGGTAT 61 60
Reverse CAGGCACCAGCCATCCTTAA
tlr6 (rat)
[NM_207604]
Forward AGAACCTTACTCATGTCCCAAAAGAC 79 60
Reverse AGATCAGATATGGAGTTTTGAGACAGACT
tlr7 (rat)
[NM_001097582]
Forward GTTTTACGTCTACACAGTAACTCTCTTCA 75 60
Reverse TTCCTGGAGGTTGCTCATGTTTT
tlr8 (rat)
[NM_001101009]
Forward GGGGTAACACACCGTCTA 150 60
Reverse GTCAAGGCGATTTCCACT
tlr9 (rat)
[NM_198131]
Forward CCGAAGACCTAGCCAACCT 70 60
Reverse TGATCACAGCGACGGCAATT
ifn-b (rat)
[NM_019127]
Forward CTTGGGTGACATCCACGACTAC 92 54
Reverse GGCATAGCTGTTGTACTTCTTGTCTT
il-6 (rat)
[NM_012589]
Forward AAGAAAGACAAAGCCAGAGTC 263 60
Reverse CACAAACTGATATGCTTAGGC
mmp3(rat)
[NM_133523]
Forward ATCCCCTGATGTCCTCG 147 54
Reverse TTTCGCCAAAAGTGCC
mmp13 (rat)
[NM_133530]
Forward TTCAACCCTGTTTACCT 293 54
Reverse TTCTTTTTCCTTGTCCC
b-actin (rat)
[NM_031144]
Forward GAGGGAAATCGTGCGTGAC 157 60
Reverse GCATCGGAACCGCTCATT
TLR3 (human)
[NM_003265]
Forward AGCCTTCAACGACTGATGCT 201 60
Reverse TTTCCAGAGCCGTGCTAAGT
b- ACTIN (human)
[NM_001101]
Forward AGTTGCGTTACACCCTTTCTTG 150 60
Reverse TCACCTTCACCGTTCCAGTTT
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min. Then the slide was incubated with an anti-TLR3
polyclonal antibody (1:100 dilution; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) or control (rabbit immu-
noglobulin G (IgG)) overnight at 4°C, and the SABC Kit
(Wuhan Boster Biological Technology, Ltd., Wuhan,
China) was used for signal amplification and visualiza-
tion according to the manufacturer’s instructions. All
sections were stained with 3,3’-diaminobenzidine and
counterstained with hematoxylin.
Administration of TLR ligands to PIA rats
Sixteen DA rats were used for polyinosinic:polycytidylic
acid (poly(I:C)) administration experiments. Briefly, half of
the rats were injected subcutaneously with 150 μL of pris-
tane, and the other half were injected with normal saline
(NS). At day 5 after pristane injection, 50 μgo fp o l y ( I : C )
(Amersham Biosciences, Piscataway, NJ, USA) in 10 μLo f
NS were injected intra-articularly into one side ankle cav-
ity of each rat in both groups, and the same volume of NS
injected into the contralateral ankle served as a control
[26]. The paws were divided into four groups: a pristane-
poly(I:C) group (injection with systematic pristane and
local poly(I:C)), a pristane-NS group, a NS-poly(I:C) group
and a NS/NS group. Arthritis symptoms were evaluated in
a blinded fashion every two to four days by using a macro-
scopic scoring system, and the perimeter changes in the
ankles and midpaws were evaluated until D26. After the
rats were killed, the synovium was collected for RNA
quantitation. In another experiment, the joints were
collected at D7 and D14 after pristane injection for patho-
logical examination.
Rat fibroblast-like synoviocyte and T-cell co-culture
Synovial fibroblasts from DA rats were isolated by col-
lagenase digestion, cultured as described previously and
used after passage 4 [27]. After four passages, the cells
were morphologically homogeneous and exhibited the
appearance of synovial fibroblasts, with a typical bipolar
configuration visualized by inverse microscopy. The pur-
ity of the cells was detected by flow cytometric staining
using antivimentin antibody [28], and the proportion of
intracellular vimentin-positive cells was more than 95%.
Spleens from PIA rats and control rats were homoge-
nized as a single-cell suspension, and red blood cells
were lysed with 0.84% NH4Cl. Next, pristane-primed T
cells and control T cells were isolated from the spleen
single-cell suspensions by using the Nylon Fiber Column
T (Wako Pure Chemical Industries Ltd., Osaka, Japan) as
described previously [29]. All T cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
s e r u m( F B S )a n d3μg/mL Concanavalin A (Con A;
Sigma, St. Louis, MO, USA) for 72 hours before use.
Fibroblast-like synoviocytes (FLSs) were seeded into six-
well plates at a density of 1 × 10
5 cells/well in DMEM sup-
plemented with 10% FBS for 24 hours, then the medium
was replaced and pristane-primed and control T cells acti-
vated by Con A were added at FLS:T cell ratios 5:1, 1:1,
1:5 and 1:10. After 24 hours of co-culturing, suspended T
cells were washed with PBS and the remaining FLSs were
used to isolate RNA for gene expression study.
Rat FLS migration ability assay
Rat FLSs were plated for 24 hours as described above, and
a1 0 0 - μL tip (Axygen Scientific, Inc., Union City, CA,
USA) was used to draw a streak uniformly in each well,
and the initial width (0 hour) of the streak was measured
using Image-Pro Plus software (Media Cybernetics, Silver
Spring, USA) and an inverted microscope (Olympus Co.,
Tokyo, Japan). Next, FLSs were co-cultured with pristane-
primed and control T cells as ratios of 1:1 and 1:5, respec-
tively, and the widths of the streaks were measured after
24 and 48 hours of co-culturing. FLS migration ability was
calculated using the formula[(the initial width)-(the width
after 24 or 48 hours of co-culturing)]/(the initial width)
*100%.
Rat FLS treatment with T-cell conditioned medium
Pristane-primed T cells and control T cells were isolated
and cultured with Con A activation for 72 hours as
described above, then the supernatant of the culture med-
ium was collected and filtered through a 0.45-μmf i l t e r
(Millipore, Eschborn, Germany). Rat FLSs were plated and
incubated with pristane-primed T-cell or control T-cell
conditioned medium for 24 hours, and TLR3, cytokine
and MMP expression of FLSs was detected by performing
real-time PCR.
Intervention of TLR3 in rat FLSs
The pGC Silencer™ U6-Neo-GFP-RNAi plasmid (Gene-
chem, Shanghai, China) containing the target sequence
of the rat tlr3 gene (ACC TCG ACC TCA CAG AGA A
as TLR3 shRNA) was used for TLR3 interference, and
the sequence of the negative control shRNA (NC-
shRNA) was TTC TCC GAA CGT GTC ACG T [24].
Briefly, FLSs were seeded into six-well plates at a density
o f1×1 0
5 cells/well and transfected with the plasmids
plus Lipofectamine™2000 reagent (Invitrogen, Carlsbad,
CA, USA). TLR3 expression in FLSs was detected after
24-hour transfection for the knockdown efficiency assay.
In T-cell co-culture experiments, TLR3-knocked-down
FLSs were co-cultured with pristane-primed T cells at a
ratio of 1:10, and the cytokine and MMP expression of
FLSs was detected by performing real-time PCR after 24
hours. In a T-cell conditioned medium stimulation
experiment, TLR3-knocked-down FLSs were incubated
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24 hours, and the gene expression of FLSs was detected
by real-time PCR.
In a TLR3 blockade assay, FLSs were seeded into six-
well plates at a density of 1 × 10
5 cells/well. FLSs were
treated with anti-TLR3 or isotype control antibodies at
the concentration of 20 μg/mL for 90 minutes before
co-culture with pristane-primed T cells at the ratio of
1:10 as described previously [24]. After 24-hour incuba-
tion, the gene expression of FLSs was detected by real-
time PCR.
Human synovial tissue preparation and FLS stimulation
Human synovial tissues were obtained from three RA
patients and three osteoarthritis (OA) patients under-
going knee joint replacement surgery. All RA patients
fulfilled the American College of Rheumatology criteria
for the classification of RA [30]. OA was diagnosed
according to the patients’ clinical features. The Human
Ethics Committee of Xi’an Jiaotong University approved
this study, and the written, informed consent of all
patients was obtained.
The FLSs from RA or OA patients were isolated as
described previously [27]. FLSs were seeded into six-well
plates at a density of 1 × 10
5 cells/well. After 24 hours, RA
FLSs were stimulated with 10 ng/mL TNF-a,1n g / m L
IL-1b,1n g / m LI F N - a,1n g / m LI F N - b,1 0μg/mL PGN,
10 μg/mL poly(I:C) and 10 ng/mL lipopolysaccharide
(LPS), respectively. RA and OA FLSs were stimulated with
1, 10 and 100 μg/mL of poly(I:C). After 24-hour stimula-
tion, cells were lysed with TRIzol reagent and TLR3
expression was detected by real-time PCR.
Statistics
Quantitative data are expressed as means ± SEM. Statisti-
cal analysis was performed by using Student’s t-test, the
Mann-Whitney U test or two-way analysis of variance.
Correlation analysis was performed by using Spearman’s
s test. P < 0.05 was regarded as statistically significant.
Results
TLR3 expression of synovium exhibited a remarkable
increase in the PIA rat model
Arthritis-susceptible DA rats were given a single subcu-
taneous injection of pristane to induce arthritis. To find
out the candidate key TLR, we analyzed TLR1 through
TLR9 mRNA expression in the synovium of PIA rats at
different time points, including D0 (normal phase), D6
(prearthritis phase), D12 (arthritis onset phase) and D26
(acute arthritis phase). Real-time PCR analysis confirmed
significant upregulation of TLR1, TLR2 and TLR5
through TLR9 and, to a lesser extent, upregulation of
TLR3 and TLR4 at D6 (Figure 1A). However, only TLR3
mRNA expression was upregulated and remained at a
high level at D12 and D26 (Figure 1A). In contrast, TLR2
and TLR4 mRNA expression were significantly decreased
a tD 1 2a n dD 2 6a n dT L R 1 ,T L R 5 ,T L R 6 ,T L R 7a n d
TLR9 expression showed significant decreases at D26
(Figure 1A). The mRNA expression of both IFN-b and
IL-6, which could be regulated by TLR3, showed signifi-
cant increases in the PIA group (D26) compared with the
control group (Figure 1B).
Next, we localized TLR3 protein expression in the
ankles of PIA rats by immunohistochemical staining,
and strong TLR3 staining was observed at synoviocytes,
especially at hyperplastic FLSs (Figure 1C). Obviously,
FLSs from PIA joints expressed TLR3 predominantly at
sites of attachment and invasion into cartilage and bone
(Figure 1C).
Poly(I:C) mediated by TLR3 aggravated the severity of PIA
Although the overexpression of TLR3 in the synovium of
PIA rats was determined, whether the TLR3 signaling
pathway is involved in the synovial inflammation of PIA
was still undefined. So, the TLR3 ligand, which could
trigger the activation of the TLR3 signaling pathway, was
used locally to confirm the role of TLR3 in synovial
inflammation. Poly(I:C) and NS were injected into differ-
ent ankle cavities of each PIA rat and each control rat.
The joints of rats in the NS/NS group did not show any
signs of arthritis. Those of rats in the NS/poly(I:C) group
exhibited mild swelling from D6 to D7, then it subsided
gradually until disappearing at D11 (Figure 2A). The pris-
tane/NS group joints developed arthritis similar to PIA,
with onset beginning on D12, and the clinical score
reached a peak at D16 and remained at a high level until
D26. Interestingly, unlike those in the NS/poly(I:C)
group, the joints of rats in the pristane/poly(I:C) group
showed severe and stable swelling in ankles from D6,
became increasingly aggravated and reached the most
serious level at D14 (Figure 2A). The clinical score of rats
in this group was significantly higher than that in the
pristane/NS group from D6 to D14. Two-way analysis of
variance confirmed a synergistic effect between the two
factors, pristane and poly(I:C), from D9 to D14. The
changes in the ankle and midpaw perimeters of each
group displayed the same tendency as their clinical scores
(Figure 2A). Compared with the pristane/NS group, the
pristane/poly(I:C) group showed a remarkable change in
ankle and midpaw perimeters from D7 to D17. Com-
pared with the NS/poly(I:C) group, we also observed a
significant change in ankle and midpaw perimeters from
D11 to D23.
The ankle sections obtained at D7 and D14 were stained
with H & E. The poly(I:C) injection groups, comprising
the NS/poly(I:C) group and the pristane/poly(I:C) group,
showed pathologic changes with abundant inflammatory
cell infiltrates and synovium hyperplasia at D7. The
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D14, but those in the pristane/NS group and the pristane/
poly(I:C) group became aggravated with obvious bone and
cartilage destruction, especially in the pristane/poly(I:C)
group (Figure 2B). The pathological scores with regard to
synovitis showed a significant difference between the NS/
poly(I:C) group, the pristane/poly(I:C) group and the NS/
NS group at D7 (Figure 2C). Not surprisingly, the pris-
tane/poly(I:C) group and the pristane/NS group had
higher synovitis scores at D14 compared with the NS/NS
Figure 1 Expression of Toll-like receptors in synovium from Dark Agouti rats with pristane-induced arthritis. (A) Expression of TLR1
through TLR9 at D0, D6, D12 and D26, and (B) expression of IFN-b and IL-6 at D0 and D26 in synovium from rats (n = 8 to 10 for each time
point) after pristane injection were measured by performing real-time PCR. Relative mRNA expression was compared with b-actin. Values shown
are means ± SEM. Levels of significance between the pristane treatment group (D6, D12 and D26) and the control group (D0) were calculated
by using Student’s t-test (*P < 0.05, **P < 0.01). (C) TLR3 protein was assessed by performing immunohistochemistry in pristane-induced arthritis
(PIA) synovium. TLR3 was strongly stained (brown, left-hand image) in synovium, especially in fibroblast-like synoviocytes (FLSs) (inset). FLSs from
PIA joints expressed TLR3 predominantly at sites of attachment and invasion into cartilage and bone (open arrowheads). Staining specificity was
assessed using isotype-matched antibodies as negative controls (right-hand image). Scale bars, 100 μm.
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articularly injected into different ankle cavities of each PIA rat and each control rat, and the arthritis clinical indexes, including clinical score,
changes in midpaw perimeter and ankle perimeter of the paws, were compared among four groups (eight paws in each group). Clinical data
were calculated using the Mann-Whitney U test (*/#P < 0.05, **/##P < 0.01, ***/###P < 0.001). *Pristane/poly(I:C) group vs. pristane/NS group.
#Pristane/poly(I:C) group vs. NS/poly(I:C) group. Shaded box represents a synergistic effect assessed by two-way analysis of variance. (B)
Representative histological images of ankle joints from each group at D7 and D14 are shown (H & E stain; original magnification, ×100). (C)
Synovitis scores were quantified for histological analysis. Pathological data were calculated using the Mann-Whitney U test (*P < 0.05).
*Comparison between groups as marked. (D) mRNA expression of TLR3 in synovium of each joint (eight joints in each group) at D26 was
measured by real-time PCR. Values are presented as means ± SEM. Gene assay results were calculated by using Student’s t-test (*P < 0.05).
Correlation between TLR3 expression and the clinical indexes was measured by using Spearman’s s analysis.
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pristane/poly(I:C) group was more severe than that of the
pristane/NS control group (Figure 2C).
Both the pristane/poly(I:C) group and the pristane/NS
group had increased TLR3 mRNA expression in syno-
vium at D26 compared with the NS/NS group (Figure
2D). In contrast, TLR3 expression did not differ between
the NS/poly(I:C) group and the NS/NS group (Figure
2D). TLR3 mRNA expression correlated with the clinical
indexes: the changes in ankle and midpaw perimeters
(Figure 2D). On the basis of the ligand stimulation
experiment, we concluded that overexpression of TLR3
in FLSs was involved in mediating arthritis development.
However, the mechanism of the induction of TLR3
expression in FLSs was still unknown, so a co-culture of
FLSs and splenic T cells was performed to investigate
whether TLR3 might be induced by infiltrated T cells
and then involved in synoviocyte activation.
Rat FLSs were activated by pristane-primed T cells with
increased TLR3 expression
Rat FLSs were co-cultured with a series of pristane-
primed or control T cells. TLR3 mRNA expression
tended to be higher with increased T cells in both co-
culture groups (Figure 3A). However, TLR3 expression
of FLSs stimulated with pristane-primed T cells showed
a higher increase compared with FLSs stimulated with
control T cells at co-culture ratios of 5:1, 1:5 and 1:10
(Figure 3A). In addition, it seemed irregular that other
TLRs were expressed at different co-culture ratios
(Additional file 1). At the ratio of 5:1, TLR4 and TLR6
expression were increased in the pristane-primed T cell
group. With the co-culture ratio at 1:1, TLR2, TLR4,
TLR6, TLR8 and TLR9 expression levels were decreased
significantly. Interestingly, except for TLR3 at the ratio
of 1:5, other TLR expression levels were not upregu-
lated. With the maximum co-culture ratio at 1:10, nearly
Figure 3 Functional analysis of rat FLSs co-cultured with pristane-primed T cells. Rat FLSs were co-cultured with pristane-primed or
control T cells, and relative mRNA expression of genes in FLSs was detected by real-time PCR. (A) TLR3 mRNA expression in FLSs was measured
24 hours after co-culture with series FLS:T-cell ratios of 5:1, 1:1, 1:5 and 1:10. (B) FLS migration ability was analyzed 24 and 48 hours after co-
culture with FLS:T-cell ratios of 1:1 and 1:5. The migration ability of FLSs co-cultured with pristane-primed T cells was compared to that co-
cultured with control T cells. (C) Cytokine (IFN-b and IL-6) and matrix metalloproteinase MMP3 and MMP13 expression were detected 24 hours
after co-culture with the cell ratio 1:10. Their expression in FLSs co-cultured with pristane-primed T cells was compared to that co-cultured with
control T cells. Data are presented as means ± SEM of four replicated determinations from three independent experiments. Levels of significance
were calculated by using Student’s t-test (*P < 0.05, ***P < 0.001).
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TLR expression regulation, wec o n s i d e r e dt h a tT L R 3i n
FLSs should be more important and more specific with
pristane-primed T-cell stimulation.
After being exposed to pristane-primed T cells for 24
a n d4 8h o u r s ,F L S sa l s os h o w e de n h a n c e dm i g r a t i o n
ability when the co-culture ratios of FLSs and T cells
were 1:1 and 1:5 (Figure 3B). Coincidentally, IFN-b, IL-6
and MMP3 expression of FLSs, which were stimulated
with pristane-primed T cells for 24 hours, showed sig-
nificantly high levels compared with those stimulated
with control T cells, whereas MMP13 expression
showed a trend toward upregulation (Figure 3C).
Obviously, TLR3 expression in FLSs was induced by
pristane-primed T-cell stimulation, and the FLSs were
activated with more cytokine and MMP secretion.
Whether synoviocyte activation was mediated by the
TLR3 signaling pathway needed to be confirmed by con-
ducting a TLR3 intervention experiment.
Intervention of TLR3 blocked the activation of FLSs
stimulated by pristane-primed T cells
First, RNA interference (RNAi) targeting rat TLR3 was
used to interfere with TLR3 expression in FLSs. After
24-hour transfection, TLR3 expression was significantly
downregulated in FLSs transfected with TLR3-shRNA
plasmid (Figure 4A). Next, FLSs transfected with
TLR3-shRNA and NC-shRNA plasmids were co-cul-
tured with pristane-primed T cells at the ratio of 1:10
for 24 hours. IFN-b, IL-6 and MMP3 mRNA expres-
sion of FLSs was significantly reduced in the TLR3-
shRNA groups compared with the NC-shRNA group,
whereas MMP13 expression only displayed a tendency
to decrease (Figure 4B).
Besides downregulation of TLR3 by RNAi, TLR3 anti-
body was used to block the TLR3 signaling pathway in
rat FLSs. With TLR3 antibody or isotype IgG preincuba-
tion, rat FLSs were co-cultured with pristane-primed T
cells at the ratio of 1:10 for 24 hours. All expression of
IFN-b, IL-6, MMP3 and MMP13 was significantly
reduced in the TLR3 antibody treatment group (Figure
4C).
Soluble inflammatory factors from T cells activated FLSs
via TLR3 in rats
To investigate whether the induction of TLR3 was due
to cell-cell interaction between FLSs and T cells or to
the stimulation of soluble factors derived from T cells,
we incubated rat FLSs with pristane-primed T-cell con-
ditioned medium (PIA group) or control T-cell condi-
tioned medium (control group), respectively, for 24
hours. TLR3 mRNA expression showed a significant
upregulation in the PIA group (Figure 5A). Meanwhile,
compared with the control group, the expression of
IFN-b, IL-6, MMP3 and MMP13 was significantly
induced in the PIA group (Figure 5B). Therefore, soluble
stimulation might be a main cause of TLR3 induction in
rat FLSs.
Next, we used TLR3-specific RNAi to interfere with
TLR3 expression in FLSs. After 24-hour transfection,
TLR3 expression showed significant downregulation in
FLSs transfected with TLR3-shRNA plasmid (Figure
5C). Then FLSs transfected with TLR3-shRNA and NC-
shRNA plasmids were incubated with pristane-primed
T-cell conditioned medium for 24 hours. Compared
with the NC-shRNA group, the results showed signifi-
cant downregulation of IFN-b and MMP-13 and, to a
lesser extent, MMP-3 in the TLR3-shRNA group (Figure
5D). However, IL-6 was not blocked by the TLR3 RNAi,
suggesting that other regulation mechanisms might be
present. Overall, the data confirmed that soluble inflam-
matory factors from T cells could be the main source
driving the activation of FLSs via TLR3 in rats.
TLR3 expression in FLSs from humans was induced by
soluble factor stimulation
Next, we collected the FLSs from RA and OA patients
to test whether TLR3 could also be induced by soluble
stimulation in the human system. RA FLSs stimulated
with TNF-a,I F N - a,I F N - b,P G N ,p o l y ( I : C )a n dL P S
showed remarkable elevation in TLR3 mRNA expres-
sion, especially with poly(I:C) (Figure 6A). FLSs stimu-
lated with IL-1b showed only slightly higher TLR3
expression (Figure 6A). Then RA and OA FLSs were
treated with 1, 10 and 100 μg/mL poly(I:C) stimulation
for 24 hours. The more than four-passaged, purified
FLSs from RA and OA patients showed no difference in
TLR3 expression (Figure 6B). However, TLR3 expression
in both groups was significantly induced by poly(I:C)
and showed a tendency to increase with the series of
poly(I:C) concentrations of RA but not OA FLSs. More-
over, TLR3 showed significantly higher expression in
RA FLSs than in OA FLSs with poly(I:C) stimulation
(Figure 6B).
Discussion
Many TLRs in previous studies of RA have been
reported to play a vital role in the pathogenesis of
arthritis. However, which TLR is key to mediating the
initiation and maintenance of joint inflammation is still
unclear, owing to the limited number of patient samples.
Accordingly, a single subcutaneous injection of pristane
in DA rats led to chronic relapsing arthritis similar to
RA in humans. We comparatively analyzed the expres-
sion of TLR1 through TLR9 in synovium during the
whole course of arthritis initiation and development to
investigate the roles of TLRs systematically and dynami-
cally in a PIA model. Nearly all TLR expression showed
Zhu et al. Arthritis Research & Therapy 2011, 13:R103
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point arthritis had not yet occurred. This finding is
probably due to the general stress reaction stimulated
by pristane, since we have observed that there is a sys-
temic inflammatory response in spleen and lymph nodes
with the activation of TLRs and the secretion of
proinflammatory cytokines [24]. Therefore, more atten-
tion to the disease onset and development phases should
be a priority. Surprisingly, we have demonstrated in the
present study that a compelling TLR is TLR3, which has
early and stable overexpression in synovium exclusively
at initiation and development stages of arthritis.
Figure 4 Blockade of T-cell-activated FLSs via TLR3 signaling pathway intervention. Rat FLSs were transfected with TLR3-shRNA plasmid
and a negative control. (A) TLR3 mRNA expression was detected 24 hours after transfection. TLR3-shRNA- and NC-shRNA plasmid-transfected
FLSs were co-cultured with pristane-primed T cells, and (B) cytokine (IFN-b and IL-6) and MMP3 and MMP13 expression were detected at 24
hours. (C) Rat FLSs were preincubated with TLR3 antibody and isotype IgG, followed by pristane-primed T-cell co-culture for 24 hours and then
expression of IFN-b, IL-6, MMP3 and MMP13 was detected. Data are presented as means ± SEM of four replicated determinations from three
independent experiments. Levels of significance were calculated by using Student’s t-test (*P < 0.05, **P < 0.01).
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related cytokine, and IL-6 showed significant increases
at D26. TLR3 has been reported to be expressed mainly
on dendritic cells and fibroblasts, as well as on murine
macrophages [31]. In the synovium of RA patients, it
has been found that most of the synoviocytes that
expressed TLR3 are synovial fibroblasts, except macro-
phages [10,15]. Consistent with previous observations in
humans, TLR3 protein expression was detected by
immunohistochemical staining in FLSs of PIA rats,
Figure 5 Activation of FLSs via TLR3 induction stimulated by pristane-primed, T-cell-conditioned medium. Rat FLSs were incubated with
pristane-primed T-cell- or control T-cell-conditioned medium for 24 hours, and (A) TLR3 and (B) functional gene expression in FLSs were
determined by using real-time PCR. Then rat FLSs were transfected with TLR3-shRNA plasmid and a negative control. (C) TLR3 mRNA expression
was detected 24 hours after transfection. (D) TLR3-shRNA plasmid- and NC-shRNA plasmid-transfected FLSs were incubated with pristane-primed
T cell condition medium, and the IFN-b, IL-6, MMP3 and MMP13 expression was detected at 24 hours. Data are presented as means ± SEM from
three independent experiments. Levels of significance were calculated by using Student’s t-test (*P < 0.05, **P < 0.01).
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of TLR3 production in inflamed synovial tissue. In other
words, the hyperplasia and activation of FLSs might be
mediated by TLR3 signaling. One possibility is that
upregulated TLR3 could recognize the RNA released
from necrotic synovial fluid cells and then activate RA
synovial fibroblasts to promote cytokine secretion and
expedite osteoclastogenesis [15,32].
According to the above findings, we suggest that TLR3
in FLSs may play an important role in the local inflam-
mation of PIA. In a previous study, intra-articular treat-
ment with poly(I:C) was found to cause a rapid and
strong synovitis in rats [26], which suggests the involve-
ment of TLR3 signaling in inflammation mediation. To
confirm that overexpression of TLR3 in FLSs is func-
tional in joint inflammation induced by pristane, we
administrated poly(I:C) locally to PIA rats and observed
the synergistic effect. The results showed that PIA rats
intra-articularly treated with poly(I:C) compared with
rats treated with poly(I:C) alone exhibited more persis-
tent inflammation and joint destruction, which might be
due to the upregulation of TLR3 expression in PIA.
Meanwhile, comparing the PIA group and the PIA/poly
(I:C) group, we found that treatment with poly(I:C) could
exacerbate arthritis, especially at the initial stage of
arthritis, according to both the clinical and pathological
results. Obviously, the above results confirm that there is
a strong synergistic effect between pristane and poly(I:C).
TLR3 expression was upregulated in both pristane treat-
ment groups, especially in the pristane/poly(I:C) group,
and significantly correlated with arthritis severity, sug-
gesting that the activation of TLR3 on fibroblasts
triggered by poly(I:C) causes more severe arthritis. These
results validate the importance of TLR3 in PIA in vivo.
However, the cause of the upregulation of TLR3 expres-
sion and the activation of FLSs in arthritis is not known
yet.
Accumulating evidence favors the involvement of an
adaptive autoimmune process in the etiopathogenesis of
RA and experimental arthritis [33,34]. Recently, several
models of spontaneous arthritis due to perturbations in
the TCR signaling pathway have been identified, and the
effector mechanisms in the model are T cell-mediated
[35]. Moreover, the vast majority of lymphocytes infiltrat-
ing RA synovium are CD4
+ ab T cells [36,37]. PIA is also
a T-cell-dependent disease which can be transferred with
CD4
+ ab T cells [38]. T cells isolated from the spleens of
PIA rats transfer severe arthritis, showing that the critical
arthritogenic change induced by pristane is present in the
spleen. Meanwhile, there is a selective accumulation of
activated CD4
+ T cells in PIA synovial membrane.
Administration of anti-CD4 antibody, but not anti-CD8
antibody, can ameliorate PIA (W Zhu, L Meng, J Tuncel,
S Carlsen, S Lu and R Holmdahl. unpublished data).
These data suggest that the splenic, pristane-primed,
arthritogenic T cells, which specifically infiltrate into
joints, might be the inflammatory trigger for FLS activa-
tion, joint destruction and arthritis chronicity. Thus, we
co-cultured the splenic T cells with rat FLSs to investi-
gate the intercellular interaction in synovial inflamma-
tion. It was a surprising finding that pristane-primed T
cells significantly elevated TLR3 expression in FLSs and
that FLSs also exhibited an enhanced migration ability
and increased cytokine and MMP secretion. In other
Figure 6 Regulation of TLR3 expression in RA FLSs stimulation by various inflammatory factors. (A) FLSs from RA patients (n = 3) were
stimulated with TNF-a, IL-1b, IFN-a, IFN-b, PGN, poly(I:C) and LPS for 24 hours, and TLR3 expression was regulated to different extents. Values
are mean ± SEM fold induction of TLR3 mRNA relative to unstimulated cells (set as control). Baseline expression (control group) was set at 1. (B)
Induction of TLR3 mRNA expression in FLSs from RA patients (n = 3) and OA patients (n = 3) with series poly(I:C) dose stimulation. Data are
presented as means ± SEM from three independent experiments. Levels of significance were calculated by using Student’s t-test (*P < 0.05, ***P
< 0.001).
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system led to the induction of FLSs in arthritic joints.
Meanwhile, we found that other TLR expression was
regulated erratically. With the exception of TLR3, TLRs
were not induced significantly under the co-culture ratio
of 1:5, suggesting that TLR3 might be preferentially
induced with pristane-primed T cell-specific stimulation.
With the maximum co-culture ratio (1:10), nearly all
TLR (but not TLR1) expression was increased, which was
probably due to the secondary inflammatory response.
Taken together with the comprehensive analysis, we con-
sidered that TLR3 should be a more important and speci-
fic TLR in FLS induction and thus we gave priority
attention to TLR3 in our following work, although we
still could not rule out other TLR roles in joint inflamma-
tion, which need to be confirmed by further studies.
Intervention of both TLR3 expression and the TLR3
signaling pathway in FLSs blocked the upregulation of
cytokines and MMPs stimulated by pristane-primed T
cells, suggesting that the TLR3 signaling pathway
induced by T cells actually caused the FLS activation.
However, the questions how T cells upregulate TLR3
expression in FLSs, and whether TLR3 induction is due
to cell-cell interaction or to T cell-derived soluble factor
stimulation, were still equivocal. Thus, we utilized the
T-cell conditioned medium instead of T cells to be
incubated with the FLSs and found that FLSs with pris-
tane-primed T-cell conditioned medium showed strong
induction of TLR3 expression and increased production
of cytokines and MMPs. The increased secretion of
IFN-b and MMPs, but not IL-6, in FLSs was blocked by
TLR3-specific RNAi. The above in vitro data suggested
that the stimulation of soluble factors derived from T
cells might be the main cause of TLR3 upregulation,
which subsequently activated FLSs, although we still
could not rule out the role of cell contact. IL-6 upregu-
lation, which could be induced by a variety of stimuli,
seemed not to depend on TLR3, suggesting that IL-6
might be regulated by other mechanisms.
The pristane-primed arthritogenic T cells which are
used to transfer arthritis could secrete IFN-g and TNF-a
with Con A stimulation in vitro, and pretreatment of
recipient rats with either anti-IFN-g or a recombinant
TNF-a receptor before transfer, ameliorated arthritis
development [38]. Other cytokines are also considered
to be involved in arthritis, however, and biological medi-
cines targeting them (such as IL-1, IL-6 and IL-17) were
developed in different clinical trials [39]. Thus, the ques-
tion of which key cytokines participate in mediating
local inflammation in joints is still interesting. In our rat
experiments, we comprehensively used inflammatory
factors to stimulate FLSs from RA patients to confirm
the universality of TLR3 induction in the human system.
All chosen factors, including proinflammatory cytokines
and ligands of TLRs, which had been reported to be
involved in RA successfully induced the upregulation of
TLR3 expression. With poly(I:C) treatment, we observed
an enhanced increase in TLR3 expression in RA FLSs
compared with OA FLSs, suggesting that TLR3 signaling
in RA FLSs has a lower activation threshold. These find-
ings validate that in RA, not only in PIA, TLR3 signaling
mediates the FLS activation induced by inflammatory
stimulation.
Conclusions
In summary, TLR3 in the synovium of PIA rats dis-
played early and persistent overexpression at the initia-
tion and development stages of arthritis. TLR3 was
localized in FLSs, and activation of the TLR3 signaling
pathway in vivo could aggravate arthritis. FLSs were
activated and made functional by the T cell-derived
inflammatory mediator via TLR3 signaling in arthritis.
Thus, TLR3 was confirmed to be an important mediator
to bridge T cells and FLSs in arthritis. These data pro-
vide a very useful experimental example to increase
understanding of the initiation and development of
synovial inflammation systemically and dynamically, and
also provide an interesting target for RA treatment.
Additional material
Additional file 1: Regulation of TLR expression in rat FLSs co-
cultured with pristane primed T cells. Rat FLSs were co-cultured with
pristane primed or control T cells, and TLR1, TLR2 and TLR4 through
TLR9 mRNA expression in FLSs was measured 24 hours after co-culture
with series cell ratios of 5:1, 1:1, 1:5 and 1:10. Their expression in FLSs co-
cultured with pristane-primed T cells was compared to that co-cultured
with control T cells. Data are presented as means ± SEM of three
replicated determinations from three independent experiments. Levels of
significance were calculated by using Student’s t-test (*P < 0.05).
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